High-Grade Gliomas in Children-A Multi-Institutional Polish Study.
Aleksandra NapieralskaAleksandra KrzywonAgnieszka Mizia-MalarzJoanna Sosna-ZielińskaEwa PawlowskaMałgorzata Anna KrawczykKatarzyna Konat-BąskaAneta KaczorowskaAnna DąbrowskaMateusz SzylbergPublished in: Cancers (2021)
Due to the rarity of high-grade gliomas (HGG) in children, data on this topic are scarce. The study aimed to investigate the long-term results of treatment of children with HGG and to identify factors related to better survival. We performed a retrospective analysis of patients treated for HGG who had the main tumor located outside the brainstem. The evaluation of factors that correlated with better survival was performed with the Cox proportional-hazard model. Survival was estimated with the Kaplan-Meier method. The study group consisted of 82 consecutive patients. All of them underwent surgery as primary treatment. Chemotherapy was applied in 93% of children with one third treated with temozolomide. After or during the systemic treatment, 79% of them received radiotherapy with a median dose of 54 Gy. Median follow-up was 122 months, and during that time, 59 patients died. One-, 2-, 5-, and 10-year overall survival was 78%, 48%, 30% and 17%, respectively. Patients with radical (R0) resection and temozolomide-based chemotherapy had better overall survival. Progression-free survival was better in patients after R0 resection and radical radiotherapy. The best outcome in HGG patients was observed in patients after R0 resection with immediate postoperative temozolomide-based chemotherapy and radical radiotherapy.
Keyphrases
- end stage renal disease
- newly diagnosed
- high grade
- ejection fraction
- chronic kidney disease
- free survival
- peritoneal dialysis
- young adults
- early stage
- machine learning
- radiation therapy
- minimally invasive
- patient reported outcomes
- squamous cell carcinoma
- patients undergoing
- big data
- artificial intelligence
- deep learning
- drug induced
- atrial fibrillation